STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3219 by analyst upside · 2026-06-29
RPRX
Royalty Pharma plc
Healthcare · Market Cap $32B · P/E 29.6x
ANALYST PRICE TARGET
+5.4%
implied upside to consensus target
Current Price $56.23
Consensus Target $59.25
Bull Target $66.0
Bear Target $46.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
5
Hold
2
Sell
0
52-Week Low $34.08
52-Week High $56.5
YTD Return +46.1%
FUNDAMENTALS
Market Cap $32B
P/E Ratio (TTM) 29.6x
Forward P/E 10.0x
EPS (TTM) $1.90
PEG Ratio 2.10
Dividend Yield 1.67%
Revenue (TTM) $2.4B
Profit Margin 33.9%
52-WEEK RANGE
52-Week Low $34.08
52-Week High $56.5
Current Price $56.23
Bear Target $46.0
Bull Target $66.0
● Now $56.23 ● Target $59.25
TRADING DATA
Avg Volume 3.7M
YTD Return +46.1%
Analyst Count 8
Consensus Buy
Upside to Target +5.4%
Last Updated 2026-06-29

ANALYST SUMMARY

Royalty Pharma plc (RPRX) is currently trading at $56.23 with a Wall Street consensus price target of $59.25, implying potential upside of 5.4% over the next 12 months. 8 analysts currently cover RPRX, with a consensus rating of Buy - 78% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $66.0, while the most cautious has a target of $46.0.

RPRX operates in the Healthcare sector with a market capitalisation of $32B. The stock is up 46.1% year-to-date and is currently trading near the upper end of its 52-week range of $34.08 – $56.5.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for RPRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citigroup — Reiterated
Buy → Buy 2026-05-07 Building track record
JP Morgan — Reiterated
Overweight → Overweight 2026-05-07 43% win rate (7 calls)
UBS — Reiterated
Buy → Buy 2026-04-21 33% win rate (6 calls)
Morgan Stanley — Reiterated
Overweight → Overweight 2026-04-10 Building track record
UBS ↑ Upgrade
Neutral → Buy 2026-01-30 33% win rate (6 calls)
Citigroup — Reiterated
Buy → Buy 2026-01-27 Building track record
TD Cowen — Reiterated
Buy → Buy 2025-12-11 Building track record
Morgan Stanley — Reiterated
Overweight → Overweight 2025-10-10 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
54
out of 100
Coverage depth
17/30
Consensus clarity
23/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →